Reversal of epigenetic silencing rescues integrase-deficient HIV-1 replication

逆转表观遗传沉默可挽救整合酶缺陷的 HIV-1 复制

基本信息

  • 批准号:
    10158875
  • 负责人:
  • 金额:
    $ 23.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-10 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

ABSTRACT After reverse transcription in the cytoplasm, retroviral DNAs enter the nucleus naked and are then detected by currently unknown innate immune factors and coated with repressive chromatin. However, retroviruses encode an integrase (IN) which allows the proviral DNA to be inserted into transcriptionally active areas of the host genome, which then results in the repressive chromatin marks on the retroviral DNA being replaced by the active marks characteristic of the flanking host chromatin. If IN activity is blocked either by mutagenesis or by a drug, then the unintegrated retroviral DNA remains covered with inhibitory chromatin and is transcriptionally silenced. This grant proposes has two goals. Firstly, I hypothesize that if unintegrated HIV-1 DNA is epigenetically silenced then it should be possible to activate that DNA, and rescue the replication of IN- HIV-1, by either directly activating the HIV-1 LTR promoter and/or by directly reversing the epigenetic silencing. We have now shown that expression of the HTLV-1 Tax protein, a potent activator of cellular NK-kB/Rel transcription factors, induces the recruitment of RelA and RelB to the NF-kB sites present in the HIV-1 LTR and also prevents or reverses the epigenetic silencing of unintegrated HIV-1 DNA, allowing IN- HIV-1 mutants to mount a robust, spreading infection in CEM-SS cells. It remains unclear whether transcriptional activation of the HIV-1 LTR occurs before or after the change in epigenetic marks on the viral DNA, and this is something we wish to address, including in primary T cells. We now report preliminary data, obtained in 293T cells, showing that the HSV-1 ICP0 protein can also rescue IN- HIV-1 gene expression, in this case by apparently directly regulating the epigenetic status of unintegrated HIV-1 DNA. We aim to extend this analysis to T cells to see if ICP0 is indeed rescuing IN- HIV-1 gene expression via a different mechanism than Tax. Finally, while the factors that recognize and silence IN- MLV have been identified by the Goff laboratory as the HUSH complex acting in concert with NP220, we show that these factors are not required to silence IN- HIV-1. A key goal of this application is therefore to perform an unbiased CRISPR/Cas genetic screen to identify the human innate immune factors that perform this task and then define their mechanism of action.
摘要 在细胞质中逆转录后,逆转录病毒DNA裸露进入细胞核, 被目前未知的先天免疫因子感染,并被抑制性染色质覆盖。然而,逆转录病毒 编码整合酶(IN),其允许前病毒DNA插入到前病毒的转录活性区域中。 宿主基因组,然后导致逆转录病毒DNA上的抑制性染色质标记被替换为 侧翼宿主染色质的活性标记特征。如果IN活性通过诱变或通过 药物,那么未整合的逆转录病毒DNA仍然被抑制性染色质覆盖, 沉默这项拨款有两个目标。首先,我假设,如果未整合的HIV-1 DNA 那么就有可能激活该DNA,拯救IN-HIV-1的复制, 通过直接激活HIV-1 LTR启动子和/或直接逆转表观遗传沉默。我们 现在已经表明,HTLV-1 Tax蛋白的表达,细胞NK-kB/Rel转录的有效激活剂, 因子,诱导RelA和RelB募集到HIV-1 LTR中存在的NF-κ B位点, 或逆转未整合的HIV-1 DNA的表观遗传沉默,使IN-HIV-1突变体能够建立一个强大的, 在CEM-SS细胞中传播感染。目前尚不清楚HIV-1 LTR的转录激活是否与HIV-1的转录水平有关。 发生在病毒DNA上的表观遗传标记发生变化之前或之后,这是我们希望解决的问题, 包括在原代T细胞中。我们现在报告在293 T细胞中获得的初步数据,表明HSV-1 ICP 0蛋白还可以拯救IN- HIV-1基因表达,在这种情况下,通过明显地直接调节 未整合的HIV-1 DNA的表观遗传状态。我们的目标是将这种分析扩展到T细胞,看看ICP 0是否确实是 通过与Tax不同的机制拯救IN- HIV-1基因表达。最后,虽然认识到 和沉默IN-MLV已被Goff实验室确定为HUSH复合物, NP 220,我们表明这些因子不是沉默IN-HIV-1所必需的。因此,该应用程序的一个关键目标是 进行无偏见的CRISPR/Cas基因筛选,以确定人类先天免疫因子, 这一任务,然后确定其作用机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRYAN R. CULLEN其他文献

BRYAN R. CULLEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRYAN R. CULLEN', 18)}}的其他基金

Reversal of epigenetic silencing rescues integrase-deficient HIV-1 replication
逆转表观遗传沉默可挽救整合酶缺陷的 HIV-1 复制
  • 批准号:
    10369728
  • 财政年份:
    2021
  • 资助金额:
    $ 23.78万
  • 项目类别:
Epitranscriptomic modification of HIV-1 transcripts: Effects of drugs of abuse
HIV-1 转录本的表观转录组修饰:滥用药物的影响
  • 批准号:
    10371249
  • 财政年份:
    2018
  • 资助金额:
    $ 23.78万
  • 项目类别:
Epitranscriptomic modification of HIV-1 transcripts: Effects of drugs of abuse
HIV-1 转录本的表观转录组修饰:滥用药物的影响
  • 批准号:
    9894777
  • 财政年份:
    2018
  • 资助金额:
    $ 23.78万
  • 项目类别:
Effect of m6A editing of RNA on influenza A virus replication
RNA m6A 编辑对甲型流感病毒复制的影响
  • 批准号:
    9296268
  • 财政年份:
    2017
  • 资助金额:
    $ 23.78万
  • 项目类别:
Disruption of latent HIV-1 proviruses using CRISPR/Cas endonucleases
使用 CRISPR/Cas 核酸内切酶破坏潜伏的 HIV-1 原病毒
  • 批准号:
    9427958
  • 财政年份:
    2015
  • 资助金额:
    $ 23.78万
  • 项目类别:
Using bacterial CRISPR/Cas endonucleases to selectively eliminate HPV-transformed cells in vivo
使用细菌 CRISPR/Cas 核酸内切酶选择性消除体内 HPV 转化细胞
  • 批准号:
    9136078
  • 财政年份:
    2015
  • 资助金额:
    $ 23.78万
  • 项目类别:
Reconstitution of a protective antiviral RNAi response in somatic human cells
重建人体细胞中保护性抗病毒 RNAi 反应
  • 批准号:
    8849841
  • 财政年份:
    2014
  • 资助金额:
    $ 23.78万
  • 项目类别:
Reconstitution of a protective antiviral RNAi response in somatic human cells
重建人体细胞中保护性抗病毒 RNAi 反应
  • 批准号:
    8762673
  • 财政年份:
    2014
  • 资助金额:
    $ 23.78万
  • 项目类别:
Role and mechanism of action of gamma herpesvirus microRNAs
γ 疱疹病毒 microRNA 的作用和作用机制
  • 批准号:
    8293437
  • 财政年份:
    2011
  • 资助金额:
    $ 23.78万
  • 项目类别:
HIV-1: microRNA interactions
HIV-1:微小RNA相互作用
  • 批准号:
    8233429
  • 财政年份:
    2010
  • 资助金额:
    $ 23.78万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 23.78万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 23.78万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 23.78万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 23.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 23.78万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 23.78万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 23.78万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 23.78万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 23.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 23.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了